What is the goal of the TOPMed program?
The goal of the TOPMed program is to generate scientific resources that will improve the understanding of heart, lung, blood, and sleep disorders and advance precision medicine. Precision medicine is an emerging approach to disease prevention and treatment that considers the unique genes and environment of each patient.
The TOPMed program collects whole-genome sequencing and other -omics data. In biology, -omics refers to measurable differences or changes in biological molecules, such as genes, metabolites, proteins, and RNA. The program will integrate -omics data with molecular, behavioral, imaging, environmental, and clinical data to improve the prevention and treatment of heart, lung, blood, and sleep disorders.
The TOPMed program will specifically support the National Heart, Lung, and Blood Institute (NHLBI) Precision Medicine Activities. The program also complements the National Institutes of Health (NIH) Precision Medicine Initiative and All of Us Research Program, which will collect data from one million or more people to help study a range of health issues and diseases.
How does the TOPMed program contribute to scientific discoveries?
The TOPMed program will support research that furthers our understanding of heart, lung, blood, and sleep disorders. The program may lead to future scientific discoveries such as:
- Biomarkers that increase or decrease the risk of heart, lung, blood, and sleep disorders
- Interactions between the environment and genes that affect health
- Potential targets for new treatments
- New ways to define heart, lung, blood, and sleep disorders or subtypes of these disorders based on molecular signatures
- Targeted ways to develop and test personalized treatments in specific patients
- Advances in precision medicine to predict, prevent, diagnose, and treat heart, lung, blood, and sleep disorders
How does the TOPMed program work?
As the first step in the TOPMed program, the NHLBI established the WGS project. The WGS project is collecting whole-genome sequencing data for individuals who have well-defined clinical phenotypes and outcomes from earlier NHLBI-funded studies. The project has sequenced about 85,000 individual genomes and plans to sequence more than 120,000.
TOPMed researchers have started releasing WGS project data through the NIH Database of Genotypes and Phenotypes (dbGaP). The dbGaP was developed to archive and distribute data from studies that have investigated the interaction of genotype and phenotype, including all genome-wide association studies supported by the NIH.
The TOPMed program has started studies to collect -omics data in a subset of WGS project participants. Currently, these -omics studies are collecting RNA, gene, and metabolite profiles from individuals who participated in the NHLBI-funded Multi-Ethnic Study of Atherosclerosis (MESA).
To help build -omics data, the NHLBI plans to review applications from researchers interested in contributing samples for the TOPMed WGS project and other -omics studies. The NHLBI is also supporting efforts to develop new ways to analyze -omics data.
The TOPMed program consortium includes many centers, including the Data Coordination Center and the Informatics Research Center that serve the entire TOPMed program. As the TOPMed program grows, the NHLBI anticipates that other centers will join the consortium.